Sustained gene expression in transplanted skin fibroblasts in rats

Gene Therapy

Volumn 6, Issue 5, 1999, Pages 840-844

  Wei, M Q ^a,b   Lejnieks, D V ^a   Ramesh, N ^a   Lau, S ^a   Seppen, J ^a   Osborne, W R A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Gene inactivation; Gene therapy; Gene transfer; Genes regulatory sequences; Retroviral vector

Indexed keywords

ADENOSINE DEAMINASE; FIBRONECTIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TRANSPLANTATION; GENE EXPRESSION; GENE TRANSFER; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; RETROVIRUS; SKIN FIBROBLAST; SKIN GRAFT;

ADENOSINE DEAMINASE; ANIMALS; CELLS, CULTURED; DNA; FIBROBLASTS; FIBRONECTINS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; PROMOTER REGIONS (GENETICS); RATS; RATS, INBRED F344; REGULATORY SEQUENCES, NUCLEIC ACID; RETROVIRIDAE; TIME FACTORS; TRANSFECTION;

ADA; ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0033049601     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300878     Document Type: Article

References (53)

1. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460.
2. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993; 62: 191-217.
3. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
4. Kohn DB. The current status of gene therapy using hematopoietic stem cells. Curr Opin Fed 1995; 7: 56-63.
5. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. In: Muzyczka N (ed). Current Topics in Microbiology and Immunology. Viral Expression Vectors, vol 158. Springer-Verlag: New York, 1992, pp 97-129.
6. Samulski RJ. Adeno-asssociated virus: integration at a specific chromosomal locus. Curr Opin Genet Dev 1993; 3: 74-80.
7. Kaplitt MG et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in mammalian brain. Nat Genet 1994; 8: 148-154.
8. Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
9. Adam MA et al. Internal initiation of translation in retroviral vectors carrying picornavirus 5′ nontranslated regions. J Virol 1991; 65: 4985-1990.
10. Morgan RA et al. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 1992; 20: 1293-1299.
11. Ramesh N et al. High-titer bicistronic vectors employing foot-and-mouth disease virus internal ribosome entry site. Nucleic Acids Res 1996; 24: 2697-2700.
12. Barr E, Tripathy S, Leiden JM. Genetically modified myoblasts for the treatment of erythropoietin-responsive anemias. J Cell Biochem 1994; (Suppl. 18A): DZ012.
13. Hamamori Y et al. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest 1995; 95: 1808-1813.
14. Naffakh N et al. Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Hum Gene Ther 1996; 7: 11-21.
15. Shull RM et al. Myoblast gene therapy in canine mucopolysaccharidosis. I: abrogation by an immune response to alpha-L-iduronidase. Hum Gene Ther 1996; 7: 1595-1603.
16. Clowes MM et al. Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest 1994; 93: 644-651.
17. Geary RL et al. Gene transfer in baboons using prosthetic vascular grafts seeded with retrovirally transduced smooth muscle cells: a model for local and systemic gene therapy. Hum Gene Ther 1994; 5: 1213-1218.
18. Osborne WRA et al. Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 1995; 92: 8055-8058.
19. Ohno T et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-784.
20. Plautz G, Nabel EG, Nabel GJ. Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation 1991; 83: 578-583.
21. Lejnieks DV et al. Granulocyte colony-stimulating factor expression from transduced vascular smooth muscle cells provides sustained neutrophil increases in rats. Hum Gene Ther 1996; 7: 1431-1436.
22. Lynch CM et al. Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: a model for gene therapy. Proc Natl Acad Sci USA 1992; 89: 1138-1142.
23. Fenjves ES et al. Systemic distribution of apolipoprotein E secreted by grafts of epidermal keratinocytes: implications for epidermal function and gene therapy. Proc Natl Acad Sci USA 1989; 86: 8803-8807.
24. Flowers MED et al. Long-term transplantation of canine keratinocytes made resistant to G418 through retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 1990; 87: 2349-2353.
25. Deng H, Lin Q, Khavari PA. Sustainable cutaneous gene therapy. Nature Biotechnol 1997; 15: 1388-1391.
26. Ramesh N et al. High-level human adenosine deaminase expression in dog skin fibroblasts is not sustained following transplantation. Hum Gene Ther 1993; 4: 3-7.
27. Palmer TD et al. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 1991; 88: 1330-1334.
28. Palmer TD, Thompson AR, Miller AD. Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood 1989; 73: 438-145.
29. St Louis D, Verma I. An alternative approach to somatic cell gene therapy. Proc Natl Acad Sci USA 1988; 85: 3150-3154.
30. Moullier P et al. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat Genet 1993; 4: 154-159.
31. Moullier P et al. Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs. Nature Med 1995; 1: 353-357.
32. Naffakh N et al. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc Natl Acad Sci USA 1995; 92: 3194-3198.
33. Fenjves ES et al. Loss of expression of a retrovirus-transduced gene in human keratinocytes. J Invest Dermatol 1996; 106: 576-578.
34. Kaleko M et al. Expression of human adenosine deaminase in mice after transplantation of genetically modified bone marrow. Blood 1990; 75: 1733-1741.
35. Osborne WRA et al. Long-term expression of human adenosine deaminase in mice after transplantation of bone marrow infected with amphotropic retroviral vectors. Hum Gene Ther 1990; 1: 31-41.
36. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse skin fibroblasts. Proc Natl Acad Sci USA 1991; 88: 4626-4630.
37. Naughton BA et al. Long-term expression of a retrovirally introduced beta-galactosidase gene in rodent cells implanted in vivo using biodegradable polymer meshes. Somat Cell Mol Genet 1992; 18: 451-462.
38. Moullier P et al. Continuous systemic secretion of a lysosomal enzyme by genetically modified mouse skin fibroblasts. Transplantation 1993; 56: 427-432.
39. Hynes RO. Fibronectins. Springer-Verlag: New York, 1990.
40. Khandjian EW et al. Fibronectin gene expression in proliferating, quiescent and SV-40 infected mouse kidney cells. Exp Cell Res 1992; 202: 464-470.
41. Kamazaki T, Kobayashi M, Mitsui Y. Enhanced expression of fibronectin during in vivo cellular aging of human endothelial cells and fibroblasts. Exp Cell Res 1993; 205: 396-402.
42. Patel RS et al. Organization of the fibronectin gene provides evidence for exon shuffling during evolution. EMBO J 1987; 6: 2565-2572.
43. Dean DC, Bowles CL, Bourgeois S. Cloning and analysis of the promoter region of the human fibronectin gene. Proc Natl Acad Sci USA 1987; 84: 1876-1880.
44. Nakajima T et al. E1A-responsive elements for repression of rat fibronectin gene transcription. Mol Cell Biol 1992; 12: 2837-2846.
45. Taylor RM, Wolfe JH. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of B-glucuronidase. Nature Med 1997; 3: 771-774.
46. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994; 91: 2567-2571.
47. Tapscott SJ et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994; 91: 8185-8189.
48. Riddel SR et al. T cell-mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV patients. Nature Med 1996; 2: 216-223.
49. Palmer TD et al. Efficient retrovirus-mediated transfer and expression of a human adenosine deaminase gene in diploid skin fibroblasts from an adenosine deaminase-deficient human. Proc Natl Acad Sci USA 1987; 84: 1055-1059.
50. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill: New York, 1995, pp 1725-1768.
51. Hock RA, Miller AD, Osborne WRA. Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood 1989; 74: 876-881.
52. Osborne WRA, Miller AD. Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans. Proc Natl Acad Sci USA 1988; 85: 6851-6855.
53. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989; 7: 980-990.